Effects of fluconazole on the pharmacokinetics of celecoxib and its carboxylic acid metabolite in different CYP2C9 genotypes

This study aimed to investigate the effects of fluconazole, a moderate inhibitor of CYP2C9 and CYP3A4, on the pharmacokinetics of celecoxib and its carboxylic acid metabolite in different CYP2C9 genotypes. A total of thirty-nine healthy Korean male volunteers were divided into three different CYP2C9...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Archives of pharmacal research Ročník 48; číslo 3; s. 224 - 233
Hlavní autoři: Cho, Chang-Keun, Kang, Pureum, Jang, Choon-Gon, Lee, Yun Jeong, Bae, Jung-Woo, Choi, Chang-Ik, Lee, Seok-Yong
Médium: Journal Article
Jazyk:angličtina
Vydáno: Seoul Pharmaceutical Society of Korea 01.03.2025
대한약학회
Témata:
Administration, Oral
Adult
Antifungal Agents - administration & dosage
Antifungal Agents - pharmacology
carboxylic acids
Carboxylic Acids - metabolism
Carboxylic Acids - pharmacokinetics
Celecoxib - administration & dosage
Celecoxib - blood
Celecoxib - pharmacokinetics
Cyclooxygenase 2 Inhibitors - administration & dosage
Cyclooxygenase 2 Inhibitors - pharmacokinetics
Cytochrome P-450 CYP2C9 - genetics
Cytochrome P-450 CYP2C9 - metabolism
Drug Interactions
fluconazole
Fluconazole - administration & dosage
Fluconazole - pharmacology
Genotype
Healthy Volunteers
Humans
Male
males
Medicine
metabolites
oral administration
pharmacokinetics
Pharmacology/Toxicology
Pharmacy
Research Article
Young Adult
약학
CYP2C9
Genotype
Celecoxib
Fluconazole
Pharmacokinetics
Celecoxib carboxylic acid
ISSN:0253-6269, 1976-3786, 1976-3786
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:This study aimed to investigate the effects of fluconazole, a moderate inhibitor of CYP2C9 and CYP3A4, on the pharmacokinetics of celecoxib and its carboxylic acid metabolite in different CYP2C9 genotypes. A total of thirty-nine healthy Korean male volunteers were divided into three different CYP2C9 genotype groups ( CYP2C9*1/*1 , *1/*3 and *3/*3 genotypes) and were enrolled in the celecoxib alone trial, celecoxib with fluconazole trial, or both. In the celecoxib alone trial, participants received a single oral dose of 200 mg celecoxib. In the celecoxib with fluconazole trial, participants received 300 mg fluconazole on day 1, 150 mg fluconazole once daily for four consecutive days (day 2–5), and a coadministration of 200 mg celecoxib with 150 mg fluconazole on day 6. Plasma concentrations of celecoxib and celecoxib carboxylic acid were determined by using HPLC–MS/MS. In the CYP2C9*1/*1 genotype group, fluconazole treatment increased AUC inf of celecoxib by 2.61-fold, and decreased CL/F by 60.4% (both p < 0.001). In the CYP2C9*1/*3 genotype group, fluconazole treatment increased AUC inf of celecoxib by 2.44-fold (p < 0.001), prolonged t 1/2 by 1.36-fold (p < 0.05), and decreased CL/F by 60.4% (p < 0.001). Fluconazole treatment increased AUC inf of celecoxib by 2.23-fold, prolonged t 1/2 by 1.64-fold, and decreased CL/F by 53.8% in the subject with CYP2C9*3/*3 genotype. C max of celecoxib carboxylic acid significantly decreased in CYP2C9*1/*1 and *1/*3 genotypes (p < 0.01 and p < 0.05, respectively), following fluconazole treatment, whereas AUC inf showed no significant changes in any CYP2C9 genotype group. In conclusion, fluconazole affected the pharmacokinetics of celecoxib in different CYP2C9 genotypes.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0253-6269
1976-3786
1976-3786
DOI:10.1007/s12272-024-01531-z